SEATTLE (April 29, 2011) – The May issue of the prestigious Cancer Gene Therapy, part of Nature Publishing Group, will include a paper on Etubics’ proprietary Adenovirus Vector Vaccine Platform (AVVP) technology, entitled “An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.”
The immunotherapy platform is currently in Phase I/II clinical trials for a colorectal cancer therapy and this paper explores the pre-clinical studies of the effectiveness of Etubics’ platform as a treatment for breast cancer. A major obstacle to Ad5 vector immunotherapy has been the presence of pre-existing Ad5 immunity, which inhibits the vector delivery system. Patients without immunity to Ad5 quickly develop immunity to Ad5 after receiving an Ad5 vaccine, thus rendering additional vaccinations w ith an Ad5 vaccine useless. Pre-clinical studies show that Etubics’ breast cancer therapeutic, Ad5[E1-, E2b-]-HER2/neu, can overcome this immunity issue and induce not only the traditional antibody response but also a potent cell mediated immunity (CMI) against breast cancer, or HER2/neu, in both Ad5 naïve and Ad5 immune animals.
In addition, Etubics also reports that its Ad5 [E1-, E2b-]-HER2/neu prevented establishment of
HER2/neu-expressing tumors and significantly inhibited progression of established tumors in Ad5 naïve and Ad5 immune mice models. The data also demonstrates that in vivo delivery of Ad5 [E1-, E2b-]-HER2/neu can induce anti-tumor associated antigen (TAA) immunity and inhibit progression of HER2 /neu expressing cancers.
Dr. Frank R. Jones, founder, Chairman and Chief Executive Officer of Etubics and senior author on the report stated “It’s been known for quite some time that cell mediated immunity can be quite beneficial for cancer therapies and we are quite excited by the data that we presented in our Cancer Gene Therapy paper as it shows that our immunotherapy platform can finally overcome the barrier of Ad immunity so we can deliver a robust cell mediate and antibody immune response.”
To view the paper online, visit Cancer Gene Therapy. Etubics pre-clinical HER2/neu studies have
been funded entirely through grants from the National Cancer Institute (NCI).
Etubics is developing the next generation in vaccines, utilizing a patented advanced generation
adenovirus vector delivery platform and a validated manufacturing human cell line, called E.C7. Etubics intends to develop vector vaccines for a variety of indications utilizing its platform technology, which has attributes that allow for broad transgene expression. Etubics is currently in Phase IIa clinical trials in the United States utilizing its first vaccine candidate for the treatment of end stage colon cancer.
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers .
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.
Investor/Media contact: Ms. Ines Tucakovic Clark Phone: (206) 838-5110 Ext. 110 firstname.lastname@example.org